Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Meningitis Clear all
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

NCT00850603
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
East Stroudsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 4, 2026, 1:44 PM EDT
Completed No phase listed Observational

Study and Surgical Treatment of Syringomyelia

NCT00011245
View directory record Official record
Conditions
Syringomyelia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort

NCT02910037
View directory record Official record
Conditions
Encephalitis, Meningitis
Interventions
mNGS for pathogen detection
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Minute to 110 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

NCT00002019
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Amphotericin B, Lipid-based, Amphotericin B
Drug
Lead sponsor
Liposome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Torrance, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 1:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 4, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety of MenACWY-CRM Vaccination in Adolescents

NCT01452464
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 21 Years
Enrollment
55,397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 9 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
35
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 4, 2026, 1:44 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 4, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

NCT03710278
View directory record Official record
Conditions
Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
Interventions
LPat Device
Device
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

NCT01442675
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 55 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
15
States / cities
Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Not applicable Interventional

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002075
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 4, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

NCT00324025
View directory record Official record
Conditions
Cryptococcal Meningitis
Interventions
Mycograb, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Birmingham, Alabama • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2008 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

NCT00874549
View directory record Official record
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age

NCT00643916
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®), A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 5 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
14
States / cities
Little Rock, Arkansas • Norwich, Connecticut • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117
View directory record Official record
Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
rLP2086
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 4, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

NCT05087056
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 14 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Ventura, California • Macon, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Not applicable Interventional

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00000708
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 4, 2026, 1:44 PM EDT
Terminated Phase 1 Interventional

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

NCT00527410
View directory record Official record
Conditions
Leptomeningeal Carcinomatosis
Interventions
RTA 744
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 4, 2026, 1:44 PM EDT
Terminated Phase 2 Interventional Results available

DepoCyt for Active Lymphomatous or Leukemic Meningitis

NCT00523939
View directory record Official record
Conditions
Neoplastic Meningitis, Lymphoma, B Cell
Interventions
cytarabine liposome injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 4, 2026, 1:44 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine or control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 4, 2026, 1:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Menactra®, Menomune®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
14 Years to 27 Years
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
20
States / cities
Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 4, 2026, 1:44 PM EDT